Cisatracurium Besylate
Cisatracurium · cisatracurium besilate · NiMbex · 1 kg - 1.5kg · Cis-AttacuriuM · Mikhail Zayats · (1R,1'R,2R,2'R)- · Cisatracurium besyL
Identifikatoren & physikalische Daten
| CAS No. | 96946-42-8 |
|---|---|
| Summenformel | C65H82N2O18S2 |
| Durchschnittliche Molmasse | 1.243,5 g/mol |
| Monoisotopische Masse | 1.242,50040612 g/mol |
| SMILES | COc1ccc(C[C@@H]2c3cc(OC)c(OC)cc3CC[N@+]2(C)CCC(=O)OCCCCCOC(=O)CC[N@@+]2(C)CCc3cc(OC)c(OC)cc3[C@H]2Cc2ccc(OC)c(OC)c2)cc1OC.O=S(=O)([O-])c1ccccc1.O=S(=O)([O-])c1ccccc1 |
| InChIKey | XXZSQOVSEBAPGS-DONVQRBFSA-L |
| PubChem CID | 62886 |
| ChEMBL | CHEMBL1200641 |
| ChEBI | CHEBI:3721 |
| EC No. | 620-579-9 |
| DTXSID | DTXSID10895045 |
Chemische & physikalische Eigenschaften
| Polarare Oberfläche (TPSA) | 258 |
|---|---|
| H-Brücken-Donoren | 0 |
| H-Brücken-Akzeptoren | 18 |
| Frei drehbare Bindungen | 26 |
| Schwere Atome | 87 |
| Formalladung | 0 |
| Komplexität | 1.560 |
| Schmelzpunkt | 90-93°C |
| Lagerbedingungen | Sealed in dry,Store in freezer, under -20°C |
| Löslichkeit | H2O: soluble1mg/mL |
| Aggregatzustand | Powder |
| Farbe | white |
| Hauptanwendungen | pharmaceutical (small molecule) |
| InChIKey | XXZSQOVSEBAPGS-UHFFFAOYSA-L |
Sicherheit & Vorschriften
| GHS-Einstufung | DangerH301 (94.9%): Toxic if swallowed [Danger Acute toxicity, oral]H319 (42.9%): Causes serious eye irritation [Warning Serious eye damage/eye irritation]P264, P264+P265, P270, P280, P301+P316, P305+P351+P338, P321, P330, P337+P317, P405, and P501 (click each P-code to see the statement)Aggregated GHS information provided per 98 reports by companies from 9 notifications to the ECHA C&L Inventory. Each notification may be associated with multiple companies.Information may vary between notifications depending on impurities, additives, and other factors. The percentage value in parenthesis indicates the notified classification ratio from companies that provide hazard codes. Only hazard codes with percentage values above 10% are shown. For more detailed information, please visit ECHA C&L website. |
|---|---|
| Hazard Classes and Categories | Acute Tox. 3 (94.9%)Eye Irrit. 2 (42.9%) |
| Drug Induced Liver Injury | Drug Induced Liver Injury Rank (DILIrank 2.0)Cisatracurium besylatevNo-DILI-concernNo matchDOI:10.1016/j.drudis.2016.02.015 |
| Effects During Pregnancy and Lactation | ◉ Summary of Use during LactationNo information is available on the use of cisatracurium during breastfeeding. Because it is short acting, highly polar and poorly absorbed orally, it is not likely to reach the breastmilk in high concentration or to reach the bloodstream of the infant. When a combination of anesthetic agents is used for a procedure, follow the recommendations for the most problematic medication used during the procedure. Consider using a cisatracurium product that has no benzyl alcohol preservative.◉ Effects in Breastfed InfantsRelevant published information was not found as of the revision date.◉ Effects on Lactation and Breastmilk |
| Wassergefährdungsklasse (WGK) | 3 |
| UN-Transportnummer | UN 2811 6.1 / PGIII |
| Zollcode | 29145090 |
| R-Sätze (R) |
Anwendungen & Verwendung
Beschreibung
Cisatracurium besylate is a new intermediate-duration non-depolarizing muscle relaxant launched in the U.S.A. for intubation and maintenance of muscle relaxation during surgery and intensive care. Cisatracurium besylate is the single 1 R cis-1'R cis isomer of the commercial preparation of atracurium, a mixture of 10 isomers. It is 3 to 5 times more potent than the mixture with similar onset and duration of action. The single isomer was also reported to have reduced propensity to release histamine and have a stable cardiovascular profile. Similar to structurally related mivacurium, cisatracurium has distinct advantages of rapid degradation, enzymatic metabolism that is independent of liver or kidney resulting in short duration of action and fast, complete recovery.
Verwenden
Cisatracurium Besylate is a nondepolarizing neuromuscular blocking agent, antagonizing the action of acetylcholine by inhibiting neuromuscular transmission.